This paper discusses the potential of Leukocyte and Platelet-Rich Fibrin Therapy (LPRF) to help treat ulcers and skin damage associated with leprosy. It warns that although LPRF may be a valuable and cost-effective treatment, it is crucial to understand potential resistance to haematologically based treatments. For physicians and health service staff operating within a biomedical paradigm, folk beliefs resisting such treatments may be inconsequential. However, research and education among marginalised and excluded populations is vital to overcome potential hesitancy and resistance to such treatments.
BT - Medicina Internacia Revuo IS - 2 LA - Eng N2 -This paper discusses the potential of Leukocyte and Platelet-Rich Fibrin Therapy (LPRF) to help treat ulcers and skin damage associated with leprosy. It warns that although LPRF may be a valuable and cost-effective treatment, it is crucial to understand potential resistance to haematologically based treatments. For physicians and health service staff operating within a biomedical paradigm, folk beliefs resisting such treatments may be inconsequential. However, research and education among marginalised and excluded populations is vital to overcome potential hesitancy and resistance to such treatments.
PB - Universala Medicina Esperanto Asocio PY - 2022 T2 - Medicina Internacia Revuo TI - Leukocyte and Platelet-Rich Fibrin (LPRF) Therapy & Leprosy:: the Need for Caution and Research Among Marginalised Groups in Low Resource Settings UR - https://interrev.com/mir/index.php/mir/article/view/207/158 VL - 30 ER -